AMSTERDAM--(BUSINESS WIRE)--Synaffix B.V., a biotechnology company focused on enabling antibody-drug conjugates (ADCs) with superior therapeutic index based on its proprietary ADC technologies, ...
PRAGUE & AMSTERDAM, March 13, 2025--(BUSINESS WIRE)--SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will be exercising its option, under its license ...
Synaffix, a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), entered into a licensing agreement with Qurient, a ...
Synaffix to receive an upfront payment of USD $4.5 million with a total deal value of up to USD $415 million plus tiered single digit royalties on sales of successfully commercialized therapies For ...
License agreement centered around development of a single ADC program Usage of Synaffix GlycoConnect®, HydraSpace® and toxSYN® ADC technologies to enhance efficacy, tolerability and target engagement ...
AMSTERDAM, THE NETHERLANDS, November 16, 2022 – Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug ...
Synaffix, a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), licensed its ADC technology to BigHat Biosciences ...
On September 25, innovative new drug developer Qurient announced that it has signed a licensing agreement with Synaffix, a subsidiary of Lonza and a clinical-stage antibody-drug conjugate (ADC) ...
Hummingbird Bioscience and Synaffix are flocking together in a new licensing pact for a next-gen antibody drug conjugate (ADC) program that gives Synaffix the chance to make up to $150 million. Under ...
Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologies Genmab secures rights for conducting research on ADCs against multiple drug targets with options for exclusive ...
AMSTERDAM, Jan. 9, 2025 /PRNewswire/ -- Synaffix B.V. ("Synaffix"), a Lonza company (SWX: LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results